Cargando…

Complete Remission Obtained with Azacitidine in a Patient with Concomitant Therapy Related Myeloid Neoplasm and Pulmonary Mucormycosis

Mucormycosis is the third cause of invasive mycosis after candidiasis and aspergillosis in AML patients, representing a poor prognostic factor associated with a high rate of fatal outcome. We report a case of a patient with AML and a concomitant pulmonary mucormycosis at diagnosis, who obtained a co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Capria, S., De Angelis, F., Gentile, G., Trisolini, S.M., Brocchieri, S., Canichella, M., Chiusolo, P., Micozzi, A., Foà, R., Meloni, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2013
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736875/ https://www.ncbi.nlm.nih.gov/pubmed/23936619 http://dx.doi.org/10.4084/MJHID.2013.048

Ejemplares similares

A Rare Case of Coexisting Breast Cancer and Refractory Acute Myeloid Leukemia
por: Ballotta, L., et al.
Publicado: (2020)

Ara-C, Idarubicine and Gentuzumab Ozogamicin (AIM) as Salvage Treatment in Advanced Acute Myeloid Leukemia Patients
por: Capria, Saveria, et al.
Publicado: (2012)

Outcome of therapy-related myeloid neoplasms treated with azacitidine
por: Fianchi, Luana, et al.
Publicado: (2012)

Reduced mortality from KPC-K.pneumoniae bloodstream infection in high-risk patients with hematological malignancies colonized by KPC-K.pneumoniae
por: Micozzi, Alessandra, et al.
Publicado: (2021)

Benefits and Safety of Empiric Antibiotic Treatment Active Against KPC-K. pneumoniae in Febrile Neutropenic Patients with Acute Leukemia Who are Colonized with KPC-K. pneumoniae. A 7-Years Retrospective Observational Cohort Study
por: Micozzi, Alessandra, et al.
Publicado: (2023)

The effect of azacitidine therapy on the M protein of MDS patients with concomitant MGUS
por: Oka, Satoko, et al.
Publicado: (2018)

Durable remission of acute myeloid leukemia in an elderly patient following a limited course of azacitidine and venetoclax
por: Ehsan, Hamid, et al.
Publicado: (2022)

Carbapenem-resistant Klebsiella pneumoniae in high-risk haematological patients: factors favouring spread, risk factors and outcome of carbapenem-resistant Klebsiella pneumoniae bacteremias
por: Micozzi, Alessandra, et al.
Publicado: (2017)

COVID-19 associated with concomitant mucormycosis and aspergillosis
por: Lai, Chih-Cheng, et al.
Publicado: (2022)

Venetoclax and Azacitidine in the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm Refractory to Conventional Therapy
por: Azad, Farhan, et al.
Publicado: (2022)

Durable response of therapy-related MDS/AML with concomitant Waldenström’s macroglobulinemia treated with venetoclax and azacitidine
por: Hirano, Mitsuhito, et al.
Publicado: (2022)

Lenalidomide, celecoxib, and azacitidine therapy for blastic plasmocytoid dendritic cell neoplasm: a case report
por: Garcia-Recio, Marta, et al.
Publicado: (2016)

Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS
por: Gregory, Gareth P., et al.
Publicado: (2019)

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine
por: Döhner, Hartmut, et al.
Publicado: (2022)

Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model
por: Ramsey, Haley E., et al.
Publicado: (2020)

Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases
por: Gangat, Naseema, et al.
Publicado: (2021)

Spontaneous Remission and Concomitant Progression in a Patient with DLBCL
por: Han, Eun Ji, et al.
Publicado: (2020)

Covid-19 vaccination in patients with immune-mediated thrombotic thrombocytopenic purpura: a single-referral center experience
por: Trisolini, Silvia Maria, et al.
Publicado: (2022)

Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report
por: Di Palma, Martina, et al.
Publicado: (2022)

Concomitant orbital aspergillosis and mucormycosis in a 17 months old immunocompetent child
por: Habroosh, Fatima A., et al.
Publicado: (2017)

A case of concomitant pulmonary tuberculosis and mucormycosis in an insulin-dependent diabetic patient
por: O, Jiménez-Zarazúa, et al.
Publicado: (2019)

CONCOMITANT PULMONARY MUCORMYCOSIS AND PULMONARY ASPERGILLOSIS IN A YOUNG PATIENT WITH COVID-19
por: FELDMAN, ERICA, et al.
Publicado: (2021)

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group
por: Pleyer, Lisa, et al.
Publicado: (2014)

Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis
por: Loscocco, Giuseppe G., et al.
Publicado: (2022)

Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE)
por: Oliva, Esther Natalie, et al.
Publicado: (2023)

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial
por: Ravandi, Farhad, et al.
Publicado: (2021)

A Personalized Risk Model for Azacitidine Outcome in Myelodysplastic Syndrome and Other Myeloid Neoplasms Identified by Machine Learning Model Utilizing Real-World Data
por: Sharplin, Kirsty, et al.
Publicado: (2023)

Successful treatment with azacitidine for the simultaneous occurrence of multiple myeloma and acute myeloid leukemia with concomitant del(5q) and the JAK2 V617F mutation
por: Oka, Satoko, et al.
Publicado: (2017)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Oncocytic Adrenocortical Neoplasm with Concomitant Papillary Thyroid Cancer
por: Podetta, Michele, et al.
Publicado: (2018)

Malignant carcinoma and skin melanoma neoplasms concomitantly in the thyroid
por: Al‐Harake, Ali, et al.
Publicado: (2021)

Reduced transmission of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-KP) in patients with haematological malignancies hospitalized in an Italian hospital during the COVID-19 pandemic
por: Micozzi, Alessandra, et al.
Publicado: (2021)

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine
por: Schlenk, R. F., et al.
Publicado: (2019)

Life-Threatening Autoimmune Hemolytic Anemia and Idhiopatic Thrombocytopenic Purpura. Successful Selective Splenic Artery Embolization
por: Molica, Matteo, et al.
Publicado: (2016)

The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many?
por: Bhatt, Anjali, et al.
Publicado: (2022)

Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial
por: Wei, Andrew H., et al.
Publicado: (2023)

Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia
por: Medeiros, Bruno C., et al.
Publicado: (2018)

Safety and efficacy of azacitidine in myelodysplastic syndromes
por: Vigil, Carlos E, et al.
Publicado: (2010)

Azacitidine: No therapeutic response: case report
Publicado: (2020)

Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia
por: Shapiro, Roman M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4o1gmpom9p3ihl3nbejeje2cvg